Functional systemic CD4 immunity is a differential factor for clinical responses to PD-L1/PD-1 blockade therapy in lung cancer
Miren Zuazo(Vicomtech), David Escors(Navarrabiomed)
Cited by 3
Related Papers
The intracellular signalosome of PD-L1 in cancer cells
|Signal Transduction and Targeted Therapy|2018|287
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen‐specific regulatory T cells, and suppresses experimental inflammatory arthritis
|Arthritis & Rheumatism|2010|66
Highly differentiated CD4 T cells Unequivocally Identify Primary Resistance and Risk of Hyperprogression to PD-L1/PD-1 Immune Checkpoint Blockade in Lung Cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2018|26